JAZZ vs the Top Picks average
| Pillar | JAZZ | Book avg | Diff |
|---|---|---|---|
| Quality | 0.60 | 0.84 | -0.24 |
| Growth | 0.88 | 0.84 | +0.04 |
| Value | 0.62 | 0.78 | -0.16 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | +0.2% |
|---|---|
| 90-day change | +0.1% |
| Forward EPS estimate | $25.77 |
Over the last 90 days, what analysts expect JAZZ to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Jazz Pharmaceuticals plc (JAZZ): score, valuation & FAQ
Jazz Pharmaceuticals plc (JAZZ) is a Biotechnology company that scores 68.8 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-), Rev (B+) and PEG (B+). On valuation, JAZZ sits about 29% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -5% annual free-cash-flow growth over the next decade.
Is JAZZ a good stock to buy?
Bull Rankings scores JAZZ 68.8 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-), Rev (B+) and PEG (B+). A score is a quantitative screen of Jazz Pharmaceuticals plc's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does JAZZ score 68.8 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). JAZZ earns its highest marks on P/E (A-), Rev (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is JAZZ overvalued or undervalued?
Based on $254.28, JAZZ sits about 29% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -5% annual free-cash-flow growth over the next decade. It trades at a 17.4x P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in JAZZ?
The stock trades at a modestly elevated PE of 17.1x despite a beta of only 0.36, and our model flags shareholder dilution, which could erode EPS if new shares are issued to fund acquisitions. A debt‑to‑equity of 0.92 adds leverage risk if cash flow slows, and the reverse DCF implies a -6% annual free‑cash‑flow growth rate—far below the 12.6% revenue growth, suggesting the market is already pricing in optimism that could reverse on any pipeline setback. A missed regulatory milestone on the oncology pipeline would confirm the bear case.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.